2023
Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes
Ding Q, Spatz E, Bena J, Morrison S, Levay M, Lin H, Grey M, Edwards N, Isaacs D, West L, Combs P, Albert N. Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes. Journal Of The American Heart Association 2023, 12: e029058. PMID: 37655510, PMCID: PMC10547320, DOI: 10.1161/jaha.122.029058.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGeneral health statusCardiovascular disease typesType 2 diabetesTreatment satisfactionDiabetes-specific qualityCardiovascular diseaseHealth statusDisease typeProspective observational study designPatient-reported health statusInverse probabilityNoninsulin antidiabetic medicationsSGLT-2i useSGLT-2i usersTreatment-weighted analysisCotransporter 2 inhibitorsSGLT-2 inhibitorsDiabetes treatment satisfactionObservational study designGreater reductionAntidiabetic medicationsDiabetes medicationsSecondary outcomesSymptom burden
2017
General and diabetes-specific stress in adolescents with type 1 diabetes
Rechenberg K, Whittemore R, Holland M, Grey M. General and diabetes-specific stress in adolescents with type 1 diabetes. Diabetes Research And Clinical Practice 2017, 130: 1-8. PMID: 28551480, PMCID: PMC5608607, DOI: 10.1016/j.diabres.2017.05.003.Peer-Reviewed Original ResearchConceptsDiabetes-specific QoLType 1 diabetesDiabetes-specific stressCommon chronic health conditionsChronic health conditionsDiabetes-specific qualitySelf-management activitiesHigh generalGlycemic controlHigher HbA1cTreatment regimenMedical recordsHealthcare providersSecondary analysisSources of stressQoLHealth conditionsDifferent interventionsBaseline dataT1D.DiabetesAdolescentsSignificant proportionGeneral stressHbA1c
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply